NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Updated: May 25, 2022
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Observational
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
ClinicalTrials.gov Identifier: NCT04827563
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.
Sponsor:
University of Chicago
ClinicalTrials.gov Identifier: NCT01816971
Official Title: Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study
First Posted : April 1, 2021
Click here to see details on ClinicalTrials.gov
Device: EndoPAT
Device: Blood Pressure Cuff
Diagnostic Test: Echocardiogram
Other: Quality of Life Assessment
Other: Blood Tests
Location
United States, Illinois